期刊文献+

胃癌组织中miR-133a-3p、miR-4317的表达及临床意义 被引量:2

The expression and clinical significance of miR-133a-3p and miR-4317 in gastric cancer
下载PDF
导出
摘要 目的检测胃癌组织中微小RNA(miR)-133a-3p和miR-4317表达情况,并探究二者的临床意义。方法收集60例胃癌患者的癌组织及其相对应的癌旁组织,采用实时荧光定量反转录PCR(RT-qPCR)技术检测组织样品中miR-133a-3p和miR-4317表达水平,同时分析miR-133a-3p和miR-4317表达与患者临床特征之间的关系,采用Kaplan-Meier生存曲线分析miR-133a-3p和miR-4317表达与患者预后的关系。结果RTqPCR试验结果显示,胃癌组织中miR-133a-3p、miR-4317相对表达量均低于癌旁正常组织,差异有统计学意义(P<0.05)。胃癌组织中miR-133a-3p表达水平与肿瘤TNM分期、淋巴结转移有关(P<0.05);miR-4317表达水平与淋巴结转移、远处转移及肿瘤TNM分期有关(P<0.05)。Kaplan-Meier生存曲线显示,miR-133a-3p高表达胃癌患者的5年生存率高于低表达者,术后生存时间长于低表达者(P<0.05);miR-4317低表达胃癌患者的5年生存率低于高表达者,术后生存时间短于高表达者(P<0.05)。结论胃癌组织中miR-133a-3p和miR-4317均表现为低表达,二者有可能作为胃癌预测和预后判定的潜在标志物,为胃癌患者的预测和预后判定提供一定的参考价值。 Objective To detect the expression of microRNA(miR)-133a-3p and miR-4317 in gastric cancer,and explore the clinical significance of the two.Methods The cancer tissues of 60 gastric cancer patients and their corresponding adjacent tissues were collected.Real-time quantitative PCR(RT-qPCR)was used to detect the expression levels of miR-133a-3p and miR-4317 in tissue samples.The relationship between the expression of miR-133a-3p and miR-4317 and clinical characteristics of patients were also analyzed.Kaplan-Meier survival curve was used to analyze the relationship between the expression of miR-133a-3p and miR-4317 and the prognosis of patients.Results The RT-qPCR results showed that the relative expressions of miR-133a-3p and miR-4317 in gastric cancer tissues were lower than those in adjacent normal tissues,the differences were statistically significant(P<0.05).The expression of miR-133a-3p in gastric cancer tissues were correlated with tumor TNM stage and lymph node metastasis(P<0.05).The expression level of miR-4317 were correlated with lymph node metastasis,distant metastasis and tumor TNM stage(P<0.05).The Kaplan-Meier survival curve showed that the 5-year survival rate of patients with high expression of miR-133a-3p was higher than that of patients with low expression,and the survival time was longer than that of patients with low expression(P<0.05).The 5-year survival rate of patients with low expression of miRNA-4317 was lower than that of patients with high expression of miR-4317,and the survival time was shorter than that of patients with high expression(P<0.05).Conclusion The expression of miR-133a-3p and miR-4317 in gastric cancer tissues is low expression.The expression levels of both miR-133a-3p and miR-4317 can be used as potential markers for prognosis and diagnosis of gastric cancer,and they can provide a reference value for the prognosis and diagnosis of gastric cancer patients.
作者 杨建华 牛广旭 郭晓娟 王静 YANG Jianhua;NIU Guangxu;GUO Xiaojuan;WANG Jing(Department of Pathology,Handan Central Hospital,Handan,Hebei 056001,China)
出处 《国际检验医学杂志》 CAS 2020年第6期702-706,共5页 International Journal of Laboratory Medicine
关键词 胃癌 miR-133a-3p miR-4317 临床特征 预后 gastric cancer miR-133a-3p miR-4317 clinical characteristics prognosis
  • 相关文献

参考文献9

二级参考文献147

  • 1詹文华,韩方海,何裕隆,李玉明,彭俊生,蔡世荣,马晋平.进展期胃癌腹主动脉旁淋巴结转移规律及其清扫对临床结局的影响[J].中华胃肠外科杂志,2006,9(1):17-22. 被引量:41
  • 2安丽文,刘永军,赵丹懿,徐惠绵,关一夫.胃癌组织VEGF-C和CXCR4的表达与淋巴结转移的关系[J].世界华人消化杂志,2007,15(18):2026-2030. 被引量:5
  • 3Peter C. Thuss-Patience,Albrecht Kretzschmar,Dmitry Bichev,Tillman Deist,Axel Hinke,Kirstin Breithaupt,Yasemin Dogan,Bernhard Gebauer,Guido Schumacher,Peter Reichardt.Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)[J].European Journal of Cancer.2011(15)
  • 4Sara Dosso,Elena Zanellato,Martina Nucifora,Renzo Boldorini,Angelica Sonzogni,Roberto Biffi,Nicola Fazio,Eraldo Bucci,Ottavio Beretta,Stefano Crippa,Piercarlo Saletti,Milo Frattini.ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy[J].Cancer Chemotherapy and Pharmacology.2013(1)
  • 5Jacques Ferlay,Isabelle Soerjomataram,Rajesh Dikshit,Sultan Eser,Colin Mathers,Marise Rebelo,Donald Maxwell Parkin,David Forman,Freddie Bray.SJWD14121600000297[J]. Int. J. Cancer . 2015 (5)
  • 6Toshihiko Doi,Kei Muro,Narikazu Boku.Multicenter Phase II Study of Everolimus in Patients With Previously Treated Metastatic Gastric Cancer. Journal of Clinical Oncology . 2010
  • 7Yasutsuna Sasaki,Tomohiro Nishina,Hirofumi Yasui,Masahiro Goto,Kei Muro,Akihito Tsuji,Wasaburo Koizumi,Yasushi Toh,Takuo Hara,Yoshinori Miyata.Phase II trial of nanoparticle albumin‐bound paclitaxel as second‐line chemotherapy for unresectable or recurrent gastric cancer[J]. Cancer Sci . 2014 (7)
  • 8Hideaki Murase,Mikito Inokuchi,Yoko Takagi,Keiji Kato,Kazuyuki Kojima,Kenichi Sugihara.Prognostic significance of the co?overexpression of fibroblast growthfactor receptors 1, 2 and 4 in gastric cancer[J]. Molecular and Clinical Oncology . 2014 (4)
  • 9Manuel Barreto Miranda,J?rg Thomas Hartmann,Salah-Eddin Al-Batran,Melanie Kripp,Deniz Gencer,Andreas Hochhaus,Ralf-Dieter Hofheinz,Kirsten Merx.Mitomycin C and capecitabine in pretreated patients with metastatic gastric cancer: a multicenter phase II study[J]. Journal of Cancer Research and Clinical Oncology . 2014 (5)
  • 10Xiao-tian Zhang,Jian Li,Yu Bai,Yu-ping Chu,Jie Li,Yan Li,Ji-fang Gong,Lin Shen.A phase II study of triweekly paclitaxel and capecitabine combination therapy in patients with fluoropyrimidine-platinum-resistant metastatic gastric adenocarcinoma[J]. Journal of Cancer Research and Therapeutics . 2013 (7)

共引文献210

同被引文献14

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部